Phase II Trial of Veliparib in Patients with Previously-Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma

PURPOSE: BRCA-associated cancers have increased sensitivity to PARP inhibitors (PARPi). This single arm, non-randomized, multicenter phase II trial evaluated the response rate of velparib in patients with previously-treated BRCA1/2 or PALB2 mutant pancreatic adenocarcinoma (PDAC). METHODS: Patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Cancer
Main Authors: Lowery, Maeve A., Kelsen, David P., Capanu, Marinela, Smith, Sloane C., Lee, Jonathan W., Stadler, Zsofia K, Moore, Malcolm J, Kindler, Hedy L., Golan, Talia, Segal, Amiel, Maynard, Hannah, Hollywood, Ellen, Moynahan, MaryEllen, Salo-Mullen, Erin E., Kinh Gian Do, Richard, Chen, Alice P., Yu, Kenneth H., Tang, Laura H., O’Reilly, Eileen M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7351022/
https://ncbi.nlm.nih.gov/pubmed/29223478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2017.11.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados